Literature DB >> 23491967

Does Systemic Inflammation Play a Role in Pediatric Psychosis?

Tatiana Falcone, Erin Carlton, Catherine Lee, Mattia Janigro, Vince Fazio, Fernando Espi Forcen, Kathleen Franco, Damir Janigro.   

Abstract

CONTEXT: Human and animal studies have suggested an underlying inflammatory mechanism for a variety of neuropsychiatric disorders, including schizophrenia. To date, most available reports focused on adult patients.
OBJECTIVE: We wished to test the hypothesis that the first psychotic episode in youth is associated with inflammation. PATIENTS: We studied patients admitted to a pediatric inpatient psychiatric unit. Patients (n=80) had new-onset psychosis diagnosed using DSM-IV TR criteria for Psychosis NOS, Schizophreniform Disorder or Schizoaffective Disorder. Patients were matched for age, race and gender with inpatient controls without psychosis within the same unit (n=66). We also compared these values to normal pediatric hematologic values. To study the role of inflammation in youth with psychosis, we collected serum samples of 28 children presenting with first-episode psychosis and compared their serum cytokine and S100B levels to eight healthy controls. MAIN OUTCOME MEASURES: In this study, we measured serum markers of systemic inflammation.
RESULTS: Leukocyte counts revealed a statistically significant increase in absolute monocytes compared to patients without psychosis (0.61 ± 0.282 k/ml vs. 0.496 ± 0.14 k/ml; p<0.01) and lymphocytes (2.51 ± 0.84 k/ml vs. 2.24 ± 0.72 k/ml; p<0.05) in patients with psychosis. All other hematologic values were similar between the groups. In addition, psychosis was characterized by increased serum levels of S100B, a peripheral marker of blood-brain barrier (BBB) damage. Several inflammatory mediators (e.g., TNF-α, IL-1β, IL-6, IL-5, IL-10, and IFN-γ) were elevated in children with psychosis.
CONCLUSIONS: These results strongly support a link between systemic inflammation, blood-brain barrier disruption and first-episode psychosis in pediatric patients.

Entities:  

Keywords:  Blood-Brain Barrier; Markers; Pediatric; Psychosis; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23491967      PMCID: PMC4899842          DOI: 10.3371/CSRP.FACA.030813

Source DB:  PubMed          Journal:  Clin Schizophr Relat Psychoses        ISSN: 1935-1232


  74 in total

1.  Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke.

Authors:  Christian Foerch; Michael T Wunderlich; Florian Dvorak; Marek Humpich; Timo Kahles; Michael Goertler; Jose Alvarez-Sabín; Claus W Wallesch; Carlos A Molina; Helmuth Steinmetz; Matthias Sitzer; Joan Montaner
Journal:  Stroke       Date:  2007-08-02       Impact factor: 7.914

2.  Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.

Authors:  J Kowalski; P Blada; K Kucia; A Madej; Z S Herman
Journal:  Schizophr Res       Date:  2001-07-01       Impact factor: 4.939

Review 3.  Cytomegalovirus and schizophrenia.

Authors:  E Fuller Torrey; Markus F Leweke; Markus J Schwarz; Norbert Mueller; Silke Bachmann; Johannes Schroeder; Faith Dickerson; Robert H Yolken
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Neonatal cytomegalovirus exposure decreases prepulse inhibition in adult rats: implications for schizophrenia.

Authors:  D M Rothschild; M O'Grady; L Wecker
Journal:  J Neurosci Res       Date:  1999-08-15       Impact factor: 4.164

5.  Serum S-100beta as a possible marker of blood-brain barrier disruption.

Authors:  M Kapural; Lj Krizanac-Bengez; G Barnett; J Perl; T Masaryk; D Apollo; P Rasmussen; M R Mayberg; D Janigro
Journal:  Brain Res       Date:  2002-06-14       Impact factor: 3.252

6.  Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

Authors:  Stéphane Potvin; Emmanuel Stip; Amir A Sepehry; Alain Gendron; Ramatoulaye Bah; Edouard Kouassi
Journal:  Biol Psychiatry       Date:  2007-11-19       Impact factor: 13.382

7.  Early cerebrovascular and parenchymal events following prenatal exposure to the putative neurotoxin methylazoxymethanol.

Authors:  Stefania Bassanini; Kerri Hallene; Giorgio Battaglia; Adele Finardi; Stefano Santaguida; Marilyn Cipolla; Damir Janigro
Journal:  Neurobiol Dis       Date:  2007-03-03       Impact factor: 5.996

8.  Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?

Authors:  Roosmarijn C Drexhage; Roos C Padmos; Harm de Wit; Marjan A Versnel; Herbert Hooijkaas; Aart-Jan van der Lely; Nico van Beveren; Roel H deRijk; Dan Cohen
Journal:  Schizophr Res       Date:  2008-05-16       Impact factor: 4.939

9.  Acetylsalicylic acid as an adjuvant therapy for schizophrenia.

Authors:  Wijnand Laan; Jean-Paul Selten; René S Kahn; Anne-Margriet Huisman; Cobi J Heijnen; Diederick E Grobbee; Huibert Burger
Journal:  Trials       Date:  2006-10-23       Impact factor: 2.279

Review 10.  Theories of schizophrenia: a genetic-inflammatory-vascular synthesis.

Authors:  Daniel R Hanson; Irving I Gottesman
Journal:  BMC Med Genet       Date:  2005-02-11       Impact factor: 2.103

View more
  11 in total

1.  S100B blood levels and childhood trauma in adolescent inpatients.

Authors:  Tatiana Falcone; Damir Janigro; Rachel Lovell; Barry Simon; Charles A Brown; Mariela Herrera; Aye Mu Myint; Amit Anand
Journal:  J Psychiatr Res       Date:  2014-12-25       Impact factor: 4.791

Review 2.  Environmental Exposures and Neuropsychiatric Disorders: What Role Does the Gut-Immune-Brain Axis Play?

Authors:  Shannon Delaney; Mady Hornig
Journal:  Curr Environ Health Rep       Date:  2018-03

Review 3.  The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.

Authors:  Sovannarath Pong; Rakesh Karmacharya; Marianna Sofman; Jeffrey R Bishop; Paulo Lizano
Journal:  Complex Psychiatry       Date:  2020-09-14

4.  Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia.

Authors:  Ahmad Ghanizadeh; Michael Berk
Journal:  Med Gas Res       Date:  2013-06-06

Review 5.  Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention.

Authors:  Adam J Walker; Yesul Kim; J Blair Price; Rajas P Kale; Jane A McGillivray; Michael Berk; Susannah J Tye
Journal:  Front Psychiatry       Date:  2014-04-09       Impact factor: 4.157

6.  Early Loss of Blood-Brain Barrier Integrity Precedes NOX2 Elevation in the Prefrontal Cortex of an Animal Model of Psychosis.

Authors:  Stefania Schiavone; Emanuela Mhillaj; Margherita Neri; Maria Grazia Morgese; Paolo Tucci; Maria Bove; Mario Valentino; Giuseppe Di Giovanni; Cristoforo Pomara; Emanuela Turillazzi; Luigia Trabace; Vincenzo Cuomo
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

Review 7.  Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.

Authors:  Katina Aleksovska; Emanuele Leoncini; Stefano Bonassi; Alfredo Cesario; Stefania Boccia; Alessandra Frustaci
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

Review 8.  Cytokine Alterations in Schizophrenia: An Updated Review.

Authors:  Sara Momtazmanesh; Ameneh Zare-Shahabadi; Nima Rezaei
Journal:  Front Psychiatry       Date:  2019-12-06       Impact factor: 4.157

9.  Peripheral Blood and Salivary Biomarkers of Blood-Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts.

Authors:  Damir Janigro; Damian M Bailey; Sylvain Lehmann; Jerome Badaut; Robin O'Flynn; Christophe Hirtz; Nicola Marchi
Journal:  Front Neurol       Date:  2021-02-04       Impact factor: 4.003

10.  Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia.

Authors:  C Greene; J Kealy; M M Humphries; Y Gong; J Hou; N Hudson; L M Cassidy; R Martiniano; V Shashi; S R Hooper; G A Grant; P F Kenna; K Norris; C K Callaghan; M dN Islam; S M O'Mara; Z Najda; S G Campbell; J S Pachter; J Thomas; N M Williams; P Humphries; K C Murphy; M Campbell
Journal:  Mol Psychiatry       Date:  2017-10-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.